35485
2,4′-DDD
PESTANAL®, analytical standard
别名:
1-(2-氯苯基)-1-(4-氯苯基)-2,2-二氯乙烷, o,p′-DDD, 氯苯二氯乙烷, 米托坦
登录 查看组织和合同定价。
选择尺寸
关于此项目
线性分子式:
(ClC6H4)2CHCHCl2
化学文摘社编号:
分子量:
320.04
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
NACRES:
NA.24
EC Number:
200-166-6
Beilstein/REAXYS Number:
2056007
InChI key
JWBOIMRXGHLCPP-UHFFFAOYSA-N
InChI
1S/C14H10Cl4/c15-10-7-5-9(6-8-10)13(14(17)18)11-3-1-2-4-12(11)16/h1-8,13-14H
SMILES string
ClC(Cl)C(c1ccc(Cl)cc1)c2ccccc2Cl
grade
analytical standard
product line
PESTANAL®
shelf life
limited shelf life, expiry date on the label
technique(s)
HPLC: suitable, gas chromatography (GC): suitable
application(s)
agriculture
environmental
format
neat
Quality Level
Gene Information
human ... CYP11A1(1583), CYP11B1(1584)
General description
2,4′-DDD is generally used to reduce the endogenous CORT neuropeptide, which might mask the total population of intracellular corticosteroid receptors in sparrows. It is an adrenal specific agent, which can find potent applications in the treatment of adrenocortical carcinoma (ACC).
Application
Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.
Legal Information
PESTANAL is a registered trademark of Merck KGaA, Darmstadt, Germany
signalword
Warning
hcodes
Hazard Classifications
Carc. 2
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
dust mask type N95 (US), Eyeshields, Gloves
Pharmacological characterization of intracellular, membrane, and plasma binding sites for corticosterone in house sparrows
Breuner.WC and Orchinik M
General and Comparative Endocrinology, 163(1), 214-224 (2009)
Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients
Haak.R.H, et al.
British Journal of Cancer, 69(5), 947-951 (1994)
Mitotane for adrenocortical carcinoma treatment
SH and MF
Current Opinion in Investigational Drugs, 6(4), 386-394 (2005)
Martin Fassnacht et al.
The New England journal of medicine, 366(23), 2189-2197 (2012-05-04)
Adrenocortical carcinoma is a rare cancer that has a poor response to cytotoxic treatment. We randomly assigned 304 patients with advanced adrenocortical carcinoma to receive mitotane plus either a combination of etoposide (100 mg per square meter of body-surface area
M Terzolo et al.
European journal of endocrinology, 169(3), 263-270 (2013-05-25)
Mitotane plasma concentrations ≥ 14 mg/l have been shown to predict tumor response and better survival in patients with advanced adrenocortical carcinoma (ACC). A correlation between mitotane concentrations and patient outcome has not been demonstrated in an adjuvant setting. To
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持